Update: WADA publishes new 2018 Prohibited List which takes effect on 1 January 2018.
Since 2004, and as mandated by World Anti-Doping Code, WADA has published an annual List of Prohibited Substances and Methods (List).The List, which forms one of the five International Standards, identifies the substances and methods prohibited in- and out-of-competition, and in particular sports. The substances and methods on the List are classified by different categories (e.g., steroids, stimulants, gene doping).
WADA’s role, through its List Expert Group and Health, Medical and Research Committee, is to facilitate a consultation period before preparing and publishing the List by 1 October in order to allow for its introduction at the start of the following year.
All Stakeholder issues and comments were discussed in detail at List Committee meetings. Further information on topics included in the Summary of Modifications and Explanatory Notes, and on many other issues or queries brought to the attention of the List Committee as part of the stakeholders comments are in the Questions & Answers on the Prohibited List.
WADA, in consultation with signatories and governments, shall establish a monitoring program regarding substances which are not on the Prohibited List, but which WADA wishes to monitor in order to detect patterns of misuse in sport.
WADA shall publish, in advance of any testing, the substances that will be monitored. Laboratories will report the instances of reported use or detected presence of these substances to WADA periodically on an aggregate basis by sport and whether the samples were collected in-competition or out–of-competition. Such reports shall not contain additional information regarding specific samples.
WADA shall make available to International Federations and National Anti-Doping Organizations, on at least an annual basis, aggregate statistical information by sport regarding the additional substances. WADA shall implement measures to ensure that strict anonymity of individual Athletes is maintained with respect to such reports. The reported use or detected presence of a monitored substance shall not constitute an anti-doping rule violation.